Insys Development Company, Inc.

Radius Pharmaceuticals, Inc.

Other

Benuvia Operations, LLC

Fresh Cut Development, LLC

Kiran Kumar Vangara

Venkat R Goskonda

Ningxin Yan

Mahesh V Patel

Nachiappan Chidambaram

Hung Q Nguyen

Benjamin J Bruno

Huaguang Li

Thrimoorthy Potta

Chandeshwari Chilampalli

Kilyoung Kim

Kongnara Papangkorn

Joel Frank

Jonathan Ogle

Samuel Akapo

Daniela Bockenstedt

Rajesh Pandya

Ningxin Yin

The present invention is directed to a self-emulsifying cannabidiol composition containing one or more surfactants. The present invention is further directed to a method of treating a disease comprising administering a composition of the present invention to a subject in need thereof. The present invention is further directed to a method of treating withdrawal symptoms.

Self-emulsifying cannabidiol formulations

The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3α-OH-5α-pregnan-20-one, or 3α-OH-5β-pregnan-20-one, or both that is sufficient to treat the CNS disorder.

Compositions and methods for treating CNS disorders

The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.

Stable cannabinoid formulations

The present disclosure is drawn to compositions and methods for treating CNS disorders. In one embodiment, an oral pharmaceutical composition can comprise a therapeutically effective amount of pregn-4-ene-3,20-dione; and a pharmaceutically acceptable carrier that provides formation of either 3&#x3b1;-OH-5&#x3b1;-pregnan-20-one, or 3&#x3b1;-OH-5&#x3b2;-pregnan-20-one, or both in an amount sufficient to treat a CNS disorder when orally administered to a subject. In another embodiment, a method of treating a CNS disorder can comprise orally administering to a subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of GABA receptor binding pregn-4-ene-3,20-dione metabolites that is sufficient to treat the CNS disorder. In another embodiment, a method of treating a CNS disorder can comprise orally administering to the subject, a therapeutically effective amount of pregn-4-ene-3,20-dione that provides an amount of 3&#x3b1;-OH-5&#x3b1;-pregnan-20-one, or 3&#x3b1;-OH-5&#x3b2;-pregnan-20-one, or both that is sufficient to treat the CNS disorder.

Compositions and methods for treating central nervous system disorders

The invention is directed to sublingual spray formulations containing ondansetron, a pharmaceutically acceptable salt thereof, and a solvent consisting of ethanol and glycerin, suitable for administration to humans, and methods for treatment with sublingual formulations.

Sublingual ondansetron spray

The present invention is directed to diclofenac sublingual spray formulations. The present invention is also directed to methods for treating pain and inflammation by administering the formulations of the present invention to patients in need thereof.

Diclofenac sublingual spray

The invention is directed to sublingual spray formulations containing ondansetron or a pharmaceutically acceptable salt thereof and water. The invention is further directed to methods for treating or preventing nausea and emesis associated with cancer treatments by administering sublingual spray formulations containing ondansetron or a pharmaceutically acceptable salt thereof to a patient in need thereof.

Ondansetron sublingual spray formulation

Growing community of inventors

Phoenix, AZ, United States of America

Kiran Kumar Vangara